Article Text


THU0008 Tnf-alpha gene polymorphism in severe and mild rheumatoid arthritis
  1. M Fabris1,
  2. L Sinigaglia2,
  3. S Sacco1,
  4. E Di Poi1,
  5. G Favret1,
  6. GF Ferraccioli1
  1. 1Division of Rheumatology-DPMSC, University of Udine, Udine, Italy
  2. 2Division of Rheumatology, University of Milan, Milan, Italy


Background TNF-α is thought to be the key driving cytokine in Rheumatoid Arthritis (RA) and recently became a therapeutic target for treatment of patients particularly resistant to conventional therapy. In our study we looked for a genetic background that should indicate some criteria to address RA patients towards more aggressive treatments with anti-TNF-α agents.

Objectives We assessed the role of the -238 and +489 TNF-α gene polymorphisms in a series of patients with severe aggressive disease who were treated with anti-TNF-α therapy because of their poor response to a DMARDs combination strategy. The phenotypes of these patients were compared to those of a cohort of patients who had a good response to Methotrexate (MTX), thus revealing a mild/moderate disease.

Methods One hundred and thirty-eight (138) RA patients and sixty-four (64) controls (Healthy Blood Donors, HBD) entered the study. RA patients were divided into 2 subgroups. Group A: 72 rheumatoids, called MTX-responders (MTX-R), who were in stable partial remission since at least six months after MTX treatment (15 mg/w weekly, range 10–25 mg/w). Stable partial remission was defined when patients had less than 3 swollen joints and a morning stiffness of less than 20’. Group B: 68 rheumatoids with still active disease (more than 6 swollen joints and a morning stiffness of at least 60’) despite 6 months of combination therapy (MTX + Sulphasalazine + Hydroxychloroquine or MTX + Cyclosporine, including low doses of prednisone, 5 mg/day). This group subsequently received anti-TNF-α therapy and was labelled as anti-TNF-treated, (TNF-T). Genotyping for -238 and +489 TNF-α polymorphisms was made according to Weiss et al.1 Statistical analyses (Odds Ratio, 95% Confidence Interval) were performed using Prism Software (Graph-Pad, S. Diego, CA 92121-USA).

Results MTX-R had an overall frequency of GG homozygousity for the -238 polymorphism of 91.6% vs 92.2% in HBD, while in TNF-T subgroup the GG genotype had a frequency of 100% (OR = 13, CI = 0.7–240, p = 0.008 vs MTX-R). The comparison between TNF-T and HBD is similarly striking (POR = 12, CI = 0.7–230, p = 0.01). The major finding concerning the +489 polymorphism is the lower frequency of the AA genotype in RA in general (OR = 4.2, CI = 1–18, p = 0.01) and in TNF-T in particular.

Conclusion The GG genotype for the -238 TNF-α polymorphism marks all patients who received anti-TNF-α therapy. This group of patients also showed a significant reduction of the AA genotype of the +489 polymorphism. This latter finding supports the hypothesis that the A allele of the +489 TNF-α intronic polymorphism is linked to a genetic setting that offers a less aggressive phenotype in RA.


  1. Weiss, et al. N Engl J Med. 1996;334:1090–94

Statistics from

Request permissions

If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.